Valuation: Intellipharmaceutics International Inc.

Market Cap 14.06L 12.07L 11.33L 10.35L 19.53L 13Cr 19.62L 1.34Cr 51.96L 6.77Cr 52.81L 51.66L 22Cr P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 36.49L 31.32L 29.39L 26.85L 50.67L 35Cr 50.91L 3.48Cr 1.35Cr 18Cr 1.37Cr 1.34Cr 58Cr EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 01/04/2007
Corporate Officer/Principal - 01/02/2014
Director TitleAgeSince
Director/Board Member - 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-11.11% - - 33
-3.59%-7.10%+61.60%+114.83% 1,06000Cr
-1.15%-1.25%+52.98%+62.41% 65TCr
-1.09%-1.15%+26.18%+79.22% 46TCr
-1.47%+0.24%+42.09%+42.09% 37TCr
-0.90%+0.05%+25.57%+41.75% 30TCr
-1.94%+1.53%+3.05%+13.24% 26TCr
-0.43%-0.46%+52.06%+71.75% 24TCr
-0.93%+1.84%-13.11%-52.28% 21TCr
-0.46%+0.33%+29.05%+92.67% 18TCr
Average -1.20%-0.66%+31.05%+51.74% 41.45TCr
Weighted average by Cap. -1.81%-2.16%+40.41%+67.97%

Financials

2021 2022
Net sales - 65.73T 56.41T 52.95T 48.36T 91.27T 62.69L 91.71T 6L 2L 31.63L 2L 2L 1.05Cr
Net income -51.45L -44.16L -41.45L -37.86L -71.45L -49Cr -71.79L -4.91Cr -1.9Cr -25Cr -1.93Cr -1.89Cr -82Cr -28.92L -24.83L -23.3L -21.28L -40.16L -28Cr -40.36L -2.76Cr -1.07Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt 11.45L 10L 9L 8L 15.91L 11Cr 15.98L 1.09Cr 42.32L 5.51Cr 43.01L 42.07L 18Cr 22.42L 19.25L 18.06L 16.5L 31.14L 21Cr 31.29L 2.14Cr 82.84L 11Cr 84.19L 82.36L 36Cr
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11